Jilin Yatai (Group) Co., Ltd. (600881.SS) is a China-based conglomerate principally engaged in building materials, real estate development, pharmaceuticals, financial services, energy, and trade. The company produces clinker, cement, concrete, cement products, aggregates, and slag powder in its building materials segment; develops residential and commercial properties, provides construction and property management services in real estate; manufactures pharmaceutical products including medical devices, health management services, Shenyi capsules, and explores new drugs such as vaccines and cardiovascular treatments through subsidiaries like Yatai Pharmaceutical; invests in securities via Northeast Securities (000686.SZ), banking through Bank of Jilin, and other financial instruments; operates in coal wholesale and energy; and conducts commerce, trade, sports culture, and e-commerce. Jilin Yatai conducts operations primarily in China, with a focus on Northeast China, and serves domestic markets including construction, healthcare, and financial sectors. Founded in 1993 and listed on the Shanghai Stock Exchange in 1995, the company is headquartered in Changchun, Jilin Province. Recent developments include the completion of an equity buyback program in late 2024 involving 16.8 million shares for CNY 27 million, aimed at stabilizing shareholder value; ongoing expansion in pharmaceuticals through sales partnerships such as with Jilin Yatai Pharmaceutical Industrial Park Management Co., Ltd. for products like Duoweining and Shunning targeting RMB 30 million in sales through 2024; and strategic focus on stabilizing traditional industries while prioritizing medicine and finance growth, including new drug R&D and pharmacy chain expansion to approximately 1,000 stores.